Natasha Halasa, MD, MPH, of Vanderbilt University Medical Center (VUMC), discusses the active population-based surveillance that the New Vaccine Surveillance Network conducts.
Natasha Halasa, MD, MPH, of Vanderbilt University Medical Center (VUMC), discusses the active population-based surveillance she helps to conduct as principal investigator (PI) of the Vanderbilt site of the New Vaccine Surveillance Network, which was established in 1999 by the CDC to predict the impact of potential new vaccines. She explained that this surveillance work helps to prepare for future illnesses affecting the pediatric population worldwide.
Halasa is also a professor of pediatrics at VUMC, Division of Pediatric Infectious Diseases. Her research focuses on determining the burden of diarrheal and respiratory illnesses in pediatric and specialized populations and how to reduce them.
Transcript
Are you a part of any ongoing or upcoming research projects in either the respiratory or diarrheal fields?
Being a part of the New Vaccines Surveillance Network, and having 7 sites across the country that continually are doing active population-based surveillance, we're prepared if something new is now affecting children, either acute gastroenteritis or acute respiratory, because we're prospectively and actively collecting samples so we can always go back in time and test for them.
Like when COVID[-19] came into play, we were able to compare what happened in years prior because we're doing this same exact thing in real time. So, we could definitely show that RSV [respiratory syncytial], flu, and other envelope viruses were definitely circulating at the time in March, April, and May [2020], but after the world shut down and community measures were implemented, those viruses went away and, over time, still stayed away. The common cold virus, rhinovirus, was a non-enveloped virus that continued to persist throughout [the pandemic] and was able to show that rhinovirus is an important cause of acute respiratory illness, especially in asthma exacerbations.
The other thing we're excited about is we're continuing to look at vaccine strategies in immunocompromised host populations. We're looking at solid organ adult and pediatric transplant recipients to see if the high-dose flu vaccine is going to be more effective than the standard dose.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More